The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Circulating Tumor DNA (CtDNA) Methylation Market By 2030 Starting From Its 2026 Size?
The circulating tumor dna (ctdna) methylation market has experienced rapid expansion in recent years. This market is projected to expand from $1.48 billion in 2025 to $1.68 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.4%. Historically, this growth has been driven by progress in methylation detection, an increase in cancer diagnostics, wider adoption of liquid biopsy techniques, heightened clinical research activities, and a rising need for personalized medicine.
The circulating tumor DNA (ctDNA) methylation market is projected to experience substantial expansion in the coming years. This market is set to reach a valuation of $2.74 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. Factors contributing to this growth during the forecast period include the advancement of targeted methylation panels, AI-powered methylation analysis, initiatives for early detection, increased oncology research, and market penetration in developing regions. Key trends anticipated for the forecast period involve epigenetic biomarker assessment, incorporation with liquid biopsy techniques, continuous tumor methylation surveillance, non-invasive approaches to cancer profiling, and sophisticated ctDNA methylation kits.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28167&type=smp
Which Market Drivers Are Supporting The Expansion Of The Circulating Tumor DNA (CtDNA) Methylation Market?
The expanding incidence of cancer is anticipated to fuel the growth of the circulating tumor DNA (ctDNA) methylation market in the foreseeable future. The rise in cancer cases stems from an aging global populace and various lifestyle-associated risk factors, such as inadequate nutrition, tobacco use, and a lack of physical activity, all of which contribute to an elevated likelihood of genetic mutations and tumor formation. Circulating tumor DNA (ctDNA) methylation assays offer a means for early and non-invasive cancer detection, facilitate precise tracking of disease progression, and assist in directing tailored treatment strategies, thereby enabling prompt and accurate clinical interventions. As an illustration, the National Cancer Institute, a US-based government entity, reported in May 2024 that the population of cancer survivors in the United States is projected to expand from 18.1 million in 2022 to 26 million by 2040. Consequently, the increasing prevalence of cancer is propelling the expansion of the ctDNA methylation market.
Which Segment Categories Define The Circulating Tumor DNA (CtDNA) Methylation Market?
The circulating tumor dna (ctdna) methylation market covered in this report is segmented –
1) By Product Type: Reagents And Kits, Instrumentations, Software And Bioinformatics Solutions, Services
2) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, Other Technologies
3) By Sample Type: Blood Samples, Urine Samples, Saliva Samples, Tissue Samples, Other Sample Types
4) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications
5) By End-User: Hospitals And Clinics, Research Laboratories, Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies, Academic Institutions
Subsegments:
1) By Reagents And Kits: Cell Free DNA Extraction Kits, Bisulfite Conversion Kits, Methylation Detection Kits, Library Preparation Kits, Targeted Enrichment Kits
2) By Instrumentations: Sequencers, Real Time Polymerase Chain Reaction Systems, Digital Polymerase Chain Reaction Systems, Microarray Scanners, Droplet Digital Polymerase Chain Reaction Systems
3) By Software And Bioinformatics Solutions: Data Analysis Software, Methylation Pattern Interpretation Software, Genomic Visualization Tools, Pipeline Automation Software, Clinical Reporting Software
4) By Services: Sample Processing Services, Sequencing Services, Bioinformatics Analysis Services, Clinical Trial Support Services, Consultation And Training Services
What Major Market Trends Are Driving Changes In The Circulating Tumor DNA (CtDNA) Methylation Market?
Major companies operating in the circulating tumor DNA (ctDNA) methylation market are concentrating their efforts on developing multi-cancer early detection (MCED) blood tests. These tests analyze cancer-specific methylation patterns in ctDNA, facilitating the early, non-invasive identification of multiple cancer types. MCED tests contribute to improved patient outcomes by detecting unique methylation signatures, thereby enabling timely intervention and guiding more precise clinical decisions. For instance, in September 2025, Exact Sciences Corporation, a US-based molecular diagnostics company, introduced Cancerguard, a multi-cancer early detection blood test integrating ctDNA methylation analysis. Cancerguard uncovers unique methylation signatures across more than 50 cancer types, providing highly sensitive and non-invasive detection, delivering actionable insights for clinicians, and supporting ongoing monitoring and treatment decisions. This launch signifies a significant step toward early intervention and enhanced survival rates through precision cancer care.
Who Are The Top Companies Competing In The Circulating Tumor DNA (CtDNA) Methylation Market?
Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled
Read the full circulating tumor dna (ctdna) methylation market report here:
How Is The Circulating Tumor DNA (CtDNA) Methylation Market Distributed Across Key Geographic Regions?
North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the circulating tumor dna (ctdna) methylation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Circulating Tumor DNA (CtDNA) Methylation Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28167&type=smp
Browse Through More Reports Similar to the Global Circulating Tumor DNA (CtDNA) Methylation Market 2026, By The Business Research Company
Tumor Infiltrating Lymphocytes Market Report 2026
Cell Culture Media Market Report 2026
https://www.thebusinessresearchcompany.com/report/cell-culture-media-global-market-report
Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model